Sponsors & Exhibitors | Orphan Drugs and Rare Diseases 2022
Sponsors & Exhibitors
Smartway designs, implements and manages global programs that empower access to innovative therapies.
We partner with pharma and biotech organizations to deliver customized programs that transform lives. These partnerships have made us a leader in the provision of Expanded Access, Early Access, Compassionate Use and Named Patient Programs across 98 countries. Over the last 20 years, we’ve gained the experience it takes to strategically advice, design, initiate and manage global or regional programs with you.
We provide end-to-end solutions to manage complex EAPs. Whatever your size and scale, we’re dedicated to empowering patient access to the right therapy
Founded in 1997, Ergomed is a complete, global Phase I-IV clinical development and trial management service partner with leading expertise in developing rare diseases and oncology drugs. Pioneers in rare disease drug development since 1998, Ergomed embodies a family & patient-centric approach to recruitment and retention with access to global patients in vital geographical areas.
To further strengthen Ergomed CRO’s strong operational footprint and expertise in rare diseases and oncology, Ergomed invested in a strategic US acquisition of MedSource CRO, fully integrated in early 2021. Ergomed has supported and managed clinical development, trial management, pharmacovigilance, and medical information services for over 300 clients in more than 100 countries. For more information about
Ergomed, please visit: https://www.ergomedplc.com/
Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health outcomes and patient wellbeing. Our global team of 750+ experts — many with PhD or PharmD degrees — work strategically alongside our client partners in medical affairs, health economics and outcomes research (HEOR), market access, and commercial teams across a wide range of therapy areas. The traits that distinguish us and allow us to be leaders in our field include deep scientific knowledge and global understanding, which together create innovative, patient-centric solutions. We have a broad range of healthcare specialist expertise across many Centers of Excellence, enabling us to support our clients through all phases of the product life cycle. And we are united as one flexible organization, harnessing the power of the collective to solve complex challenges.
TCRS is a UK-based, full-service, international CRO that supports biopharma companies in the clinical development of their novel products. We have strong expertise in the management of a broad range of clinical trials and a network of tried and tested sites in the UK and internationally.
Illingworth Research Group is a provider of patient-centric clinical research solutions. Services are tailored to clinical requirements but can include: mobile research nursing, patient concierge, and medical photography, for example. These services are operational in 45 countries and concentrate on taking the trail to the patient or making trial participation easier and more accessible to patients and their families.
Patient centricity is a vital part of our mission and has been so for 20 years. Our Research Nursing support focuses on bringing the trial to the patient in their home, school, or workplace. This can enhance both patient recruitment and retention. Our medical photography team offers an alternative approach by using imagery and video footage within the clinical trial. Imagery can be used in a range of applications concentrated within but not exclusive to dermatological trials.
Real World Health is an analytics company that builds research platforms using curated, real-world evidence collated from specialist treatment centres across the US and UK.
We have worked with clinicians and other stakeholders in rare and ultra rare/rare diseases to provide our clients with the evidence and analytical tools they need.
Our solutions are delivered via a data science platform, where our team of data scientists, epidemiologists and clinical advisors can tailor a suite of analytical tools to support each phase of drug development
Our expertise is within the following areas:-
- Early Access to Medicines Schemes and Innovative Contracting
- Unmet Needs Analyses
- Clinical Trial Planning and Optimisation
- Epidemiology Models
- AI and Machine Learning
Pilloxa is a technological, regulatory, and legal platform for pharma to create dynamic apps to support patients and learn from user data. We provide innovators with the tools and insights to enable sustained learning within health so that our customers can focus on patient needs and how to best support them. Agile and affordable, pricing starts at €2500 a month and it takes only one month to launch a branded patient app with us.
Pulse Infoframe Inc (Pulse) believes that collaboration cures disease and Pulse enables such collaboration. A new style of healthcare informatics company, Pulsebuilds and supports global, healthcare ecosystems. Its solution, healthie™, empowers consortia of pharmaceutical and medical device companies, researchers, clinicians, advocacy groups and patients, by aggregating information from a variety of sources and then, delivering key healthcare insights – real-time — derived from these data. For patients with rare diseases, Pulse’sglobal coverage is critical. Already great strides have been made in characterizing rare diseases using Pulse’s global and national registries. These insights help professionals to advance medical research, focus clinical trial recruitment, assist advocacy groups in their dealings with policymakers and provide real-world evidence. Please visit pulseinfoframe.com